CD274 and non-small cell lung carcinoma: Other ICIs approved in Japan were for monotherapy of previously treated, unresectable advanced/metastatic NSCLC regardless of PD-L1 expression, including nivolumab monotherapy (December 2015) and, later, atezolizumab monotherapy (April 2018).